Health Sciences Centre

Summary

Health Sciences Centre is a medical facility located in WINNIPEG, Manitoba. This center is recognized for care of Crohn's Disease, Chronic Kidney Disease, Sepsis, Stroke, Diabetes and other specialties. Health Sciences Centre is involved with conducting 141 clinical trials across 481 conditions. There are 20 research doctors associated with this hospital, such as Sarvesh Logsetty, MD, Jai Shankar, MD FRCPC, Ryan Zarychanski, MD, and Tanya Sala, MD.

Top PIs

Clinical Trials running at Health Sciences Centre

Stroke

Chronic Kidney Disease

Deep Partial Thickness Burn

Sepsis

Postoperative Pain

Depression

Spinal Cord Injury

Critical Illness

Burns

Human Papillomavirus

Blood Thinners

for Atrial Fibrillation

This trial is testing whether taking blood-thinning pills can prevent strokes and other heart issues in patients who have temporary irregular heartbeats and are at risk of stroke after surgery. These pills are a recent breakthrough in preventing strokes.

Recruiting

3 awards

Phase 4

4 criteria

NoNO-42

for Stroke

ACT-42 is a domain of the ACT-GLOBAL platform (NCT06352632). This trial is a Phase 2b, multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled single-dose adaptive trial. A total of up to 600 male and female participants aged ≥ 18 to ≤ 90 years harboring an acute ischemic stroke who are eligible for an intravenous thrombolytic with or without endovascular thrombectomy therapy will be enrolled within 4.5 hours of stroke onset/last known well.

Recruiting

1 award

Phase 2

3 criteria

Recombinant Factor VIIa

for Hemorrhagic Stroke

The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy. FASTEST Part 2 is an extension of the FASTEST Trial where the subgroups include only those treated within 2 hours with a positive spot sign on a baseline CT angiogram.

Recruiting

1 award

Phase 3

2 criteria